IRWD
Ironwood Pharmaceuticals Inc Health Care Pharmaceutical Preparations Russell 3000
$3.50Close
$570.7MMarket cap
$1.50 – $5.3952-week range
Nov 5, 2026Next report · before the open
Highlights
Strengths
- Earnings growing EPS +130% year on year
Cautions
- Not in an uptrend 1 of 8 trend conditions
- Far from its high 35% below its 52-week high
- Results soon Nov 5, 2026, in 4 days
- Financial distress Altman Z″ in the distress zone
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
35%
1wk
up 1.2%
price change
1mo
down 11.8%
price change
12-month return
up 133%
market up 11% ·
its own up 121%
F-score
—
— Not assessed
Altman Z
-3.72
Elevated risk
P/E
23.8×
price / earnings
PEG
0.01
P/E / EPS growth
P/B
—
price / book
Earnings yield
up 27.7%
EBIT / enterprise value
Cheaper than
98%
of the market · markedly cheap
Revenue growth
down 16%
year on year
EPS growth
up 130%
latest quarter
Sales growth
up 33%
latest quarter · -126 pts
ROE
—
return on equity
Free cash margin
up 43%
$127.0M FCF
D/E
—
long-term debt / equity
Net debt / EBITDA
-2.2×
net cash
Interest cover
—EBIT / interest
Trade setup
ATR%
4.9%
$0.17 a day · 2×ATR $3.16
RS
59 / 99
vs the universe
Trend
1 / 8
trend template
Relative volume
0.8×
vs 50-day average
Up/down volume
1.29
50 sessions
Implied move
—
no option chain · report Nov 5, 2026
Trend template · 1 of 8
- At least 30% above the 52-week low: passes
Screen verdict
Did not qualify for any screen.
Warning signs
- Liabilities exceed assets Shareholders' equity is negative at -$261.8M as of Dec 31, 2025. What is left for shareholders after creditors is, on the balance sheet, less than nothing.
- Bankruptcy model reads distressed The Altman score sits inside the range historically associated with financial distress. It is used here only to exclude, never to rank, and it is a statistical band rather than a prediction about this company.
- Revenue shrinking Revenue fell 15.7% over the year, from $351.4M to $296.2M.
Last reported
Aug 6, 2026
Results reaction
Aug 6, 2026+4% vs market2 sessions after results
Financials
- Net 8%
- Free cash 43%
- Cash
- Long-term debt
| FY2020Dec 31, 2020 | FY2021Dec 31, 2021 | FY2022Dec 31, 2022 | FY2023Dec 31, 2023 | FY2024Dec 31, 2024 | FY2025Dec 31, 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $389.5M | $413.8M | $410.6M | $442.7M | $351.4M | $296.2M |
| Gross margin | 99% | — | — | — | — | — |
| Operating income | $142.9M | $232.3M | $250.3M | -$945.4M | $93.1M | $98.5M |
| Net income | $106.2M | $528.4M | $175.1M | -$1.0B | $880,000 | $24.0M |
| Net margin | 27% | 128% | 43% | -233% | 0% | 8% |
| Earnings per share | $0.66 | $3.21 | $0.94 | -$6.64 | $0.01 | $0.15 |
| Free cash flow | $167.0M | $261.6M | $273.6M | $183.2M | $103.4M | $127.0M |
| Free cash margin | 43% | 63% | 67% | 41% | 29% | 43% |
| Cash | $362.6M | $620.1M | $656.2M | $92.2M | $88.6M | $215.5M |
| Long-term debt | $430.3M | $454.2M | $396.3M | $397.9M | $199.0M | — |
| Shareholders' equity | $62.6M | $605.9M | $652.4M | -$346.3M | -$301.3M | -$261.8M |
| Shares outstanding | 160.62m | 162.04m | 154.03m | 156.35m | 160.21m | 163.06m |
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Aug 6, 2026 | Quarterly ↗ | Jun 30, 2026 | 37d |
| May 7, 2026 | Quarterly ↗ | Mar 31, 2026 | 37d |
| Feb 26, 2026 | Annual ↗ | Dec 31, 2025 | 57d |
| Nov 10, 2025 | Quarterly ↗ | Sep 30, 2025 | 41d |
| Aug 11, 2025 | Quarterly ↗ | Jun 30, 2025 | 42d |
| May 12, 2025 | Quarterly ↗ | Mar 31, 2025 | 42d |
| Mar 31, 2025 | Annual ↗ | Dec 31, 2024 | 90d |
| Nov 7, 2024 | Quarterly ↗ | Sep 30, 2024 | 38d |
| Aug 8, 2024 | Quarterly ↗ | Jun 30, 2024 | 39d |
| May 9, 2024 | Quarterly ↗ | Mar 31, 2024 | 39d |
| Feb 16, 2024 | Annual ↗ | Dec 31, 2023 | 47d |
| Nov 9, 2023 | Quarterly ↗ | Sep 30, 2023 | 40d |
Current reports
| Filed | Disclosed |
|---|---|
| Oct 16, 2026 | Director or officer change ↗ |
| Aug 6, 2026 | Results ↗ |
| Jun 18, 2026 | Director or officer change · Shareholder vote ↗ |
| Jun 15, 2026 | Other events ↗ |
| May 13, 2026 | Director or officer change ↗ |
| May 7, 2026 | Results ↗ |
| Mar 11, 2026 | Other events ↗ |
| Feb 25, 2026 | Results ↗ |
| Jan 2, 2026 | Results ↗ |
| Dec 23, 2025 | Material agreement · Other events ↗ |
| Nov 26, 2025 | Other events ↗ |
| Nov 10, 2025 | Results ↗ |